CRISIL Upgrades Mankind Pharma ESG Rating to Strong (64/100)
Mankind Pharma announced CRISIL ESG Ratings upgraded its ESG score to 64/100, moving the company from Adequate to the Strong category; the score improved from 57 and the core ESG score rose to 71 from 60. In Q1 FY27, revenue grew to ₹4,031 crore (+12.89% YoY), alongside operational integration of foreign clinical and R&D pipelines.